BC Partners in exclusive talks to buy Biogaran from Servier

BC Partners in exclusive talks to buy Biogaran from Servier

BC Partners has entered exclusive negotiations with Servier to acquire Biogaran, the French leader in generic medications. This move comes less than a year after Servier officially abandoned plans to sell the subsidiary [1].

Biogaran, a strategic asset for Servier, generates approximately €1 billion in annual revenue, with 99% of its sales occurring in France. The company's significance extends beyond its financial performance, as it supports a network of around 30 subcontractors in the country [1].

The potential sale of Biogaran to a foreign entity, particularly an Indian company, had previously sparked controversy and political resistance. However, the current negotiations with BC Partners, a European private equity firm, suggest a shift in the landscape [1].

This development underscores the evolving dynamics in the pharmaceutical industry, where strategic acquisitions and partnerships are increasingly common. The deal, if finalized, could have significant implications for the European pharmaceutical market and the broader healthcare sector.

References:
[1] https://www.lefigaro.fr/societes/un-an-apres-un-psychodrame-politico-economique-servier-cede-finalement-biogaran-au-fonds-bc-partners-20250730